tbuckley/cabot-search huggingface dataset:
Treating Disturbances in the Relationship Between Mothers With Bulimic Eating Disorders and Their Infants: A Randomized, Controlled Trial of Video Feedback
Authors: Alan Stein, Helen Woolley, Robert Senior, Leezah Hertzmann, Mary Lovel, Joanna Lee, Sandra Cooper, Rebecca Wheatcroft, Fiona Challacombe, Priti Patel, Rosemary Nicol-Harper, Pia Menzes, Anne Schmidt, Edmund Juszczak, Christopher G. Fairburn
Journal: American Journal of Psychiatry (2006)

Objective: Maternal eating disorders interfere with parenting, adversely affecting mother-infant interaction and infant outcome. This trial tested whether video-feedback treatment specifically targeting mother-child interaction would be superior to counseling in improving mother-child interaction, especially mealtime conflict, and infant weight and autonomy. Method: The participants were 80 mothers with bulimia nervosa or similar eating disorder who were attending routine baby clinics and whose infants were 4–6 months old. They were randomly assigned to video-feedback interactional treatment or supportive counseling. Both groups also received guided cognitive behavior self-help for their eating disorder. Each group received 13 sessions. The primary outcome measure was mealtime conflict; secondary outcome measures were infant weight, aspects of mother-infant interaction, and infant autonomy. Results: Seventy-seven mothers were followed up when their infants were 13 months old. The video-feedback group exhibited significantly less mealtime conflict than the control subjects. Nine of 38 (23.7%) in the video-feedback group showed episodes of marked or severe conflict, compared with 21 of 39 (53.8%) control subjects (odds ratio=0.27, 95% confidence interval=0.10 to 0.73). Video feedback produced significant improvements in several other interaction measures and greater infant autonomy. Both groups maintained good infant weight, with no differences between groups. Maternal eating psychopathology was reduced across both groups. Conclusions: Video-feedback treatment focusing on mother-infant interaction produced improvements in interaction and infant autonomy, and both groups maintained adequate infant weight. To the authors' knowledge, this is the first controlled trial to show key improvements in interaction between mothers with postnatal psychiatric disorders and their infants.
Architectural and Functional Heterogeneity of Hematopoietic Stem/Progenitor Cells in Non-Del(5q) Myelodysplastic Syndromes
Authors: Virginie Chesnais, Marie-laure Arcangeli, Caroline Delette, Alice Rousseau, M'boyba Khadija Diop, Andrea Lefevre, Meyling H. Cheok, Nicolas Chapuis, Laurence Legros, Sophie Raynaud, Lise Willems, Didier Bouscary, Evelyne Lauret, Olivier A. Bernard, Olivier Kosmider, Francoise Pflumio, Michaela Fontenay
Journal: Blood (2016)
MA 02.07 A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
Authors: A. Lisberg, J. Hunt, N. Reese, T. Wang, P. Coluzzi, M. Spiegel, K. Bornazyan, J. Carroll, J. Madrigal, B. Ledezma, M. Mendenhall, J. Bui, H. Lu, A. Cummings, Z. Noor, J.W. Goldman, E. Garon
Journal: Journal of Thoracic Oncology (2017)
Abstract 423: The Valosin-containing Protein Attenuates Chronic Pressure Overload-induced Cardiac Remodeling and Heart Failure via Activating mTORC2 Pathway
Authors: Ning Zhou, Ben Ma, Shaunrick Stoll, Hongyang Shu, Tristan Hays, Hongyu Qiu
Journal: Circulation Research (2017)

Aims: The pressure overload induced cardiac hypertrophy is a key risk factor for heart failure. However, the mechanism involved remains largely unknown. We previously showed that overexpression of valosin-containing protein (VCP) promotes cardiomyocytes survival in vitro . Here we tested the hypothesis that VCP protects heart against pressure overload-induced heart failure via promoting pro-survival signaling in cardiomyocyte in vivo . Methods and Results: VCP expression were found to be notably decreased in left ventricle (LV) tissues of dilated cardiomyopathy patients compared to healthy donor at both the mRNA and protein levels. A transgenic mouse (TG) with a cardiac specific overexpression of VCP was generated and compared to its litter-matched wild-type (WT). Pressure overload was induced by transverse aortic constriction (TAC) in mice for 5 weeks and sham control was included. Cardiac structure and function were measured by echocardiography and hemodynamic analysis. After 5 week TAC, compared to sham control, WT mice developed a dilated cardiac hypertrophy and cardiac dysfunction, reflected by a significant increase in LV chamber diameter, wall thickness and the ratio of LV weight/ tibia length, and a decrease in ejection fraction (71% vs 51%) as well as an increase in ratio of lung weight /tibia length, a marker of heart failure (all, P&lt;0.01 vs WT sham). However, these pressure overload induced cardiac remodeling and dysfunction were significant suppressed in VCP TG TAC mice (P&lt;0.05 vs WT TAC). Mechanistically, compared to sham control, VCP expression in LV tissues was found to be significant decreased in WT TAC mice, but not in VCP TG mice. VCP TG TAC mice showed a significant decrease in apoptosis of cardiomyocytes vs WT TAC mice (p&lt;0.05). In addition, overexpression of VCP increased the phosphorylation of AKt at 473 and the expression of protein kinase C α in VCP TG mouse heart in vivo and in isolated cardiomyocytes in vitro which was abolished by the deletion of Rictor, indicating an activation of mammalian target of rapamycin complex 2 (mTORC2) in cardiomyocytes. Conclusion: Overexpression of VCP prevents TAC-induced cardiac remodeling and heart failure via a pro-survival mechanism involving mTORC2 signaling pathway.
Optic and peripheral neuropathy in Cuba
Authors: A. Espinosa
Journal: JAMA (1994)

<h3>To the Editor.</h3> —We write concerning the epidemic of neuropathy that has been affecting Cubans since 1991. As of June 18, 1993, more than 45000 cases had been reported, with 86.6% of the patients between the ages of 25 and 64 years. The principal clinical forms are optic neuropathy and myeloneuropathy. This condition has been called epidemic neuropathy.<sup>1</sup> We believe that Leber's disease can be used as a theoretical model to explain greater susceptibility of certain persons to epidemic neuropathy. It is possible that the risk of developing epidemic neuropathy is higher in genetically susceptible persons and those with Leber's disease than among those lacking this genotype. Nikoskelainen et al<sup>2</sup>observed that the frequency of preexcitation syndromes in patients with Leber's disease and their families was unusually high. The fact that this disease is mitochondrial would explain the electrocardiographic changes in the patients.<sup>3</sup> With this background information
BY-LAW IV.—THE PUBLICATION OF PAPERS AND REPORTS.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sports medicine
Authors: J. B. Ryan
Journal: JAMA (1992)

Sports medicine combines nonsurgical and surgical subspecialties that deal with the health care issues of athletes (young or old, competitive or recreational, professional or amateur, and healthy or injured). This update reviews the recent advances in the care of the female athlete, the drug problem in sports, new techniques of knee rehabilitation, and treatment of meniscus tears. Engstrom et al<sup>1</sup>noted that 41 elite female soccer players experienced a higher rate of injuries (12 per 1000 hours of exposure) than a comparable group of male soccer players (five per 1000 hours). Approximately one in six of these female players sustained a major knee ligament or meniscus tear. Ireland and Wall<sup>2</sup>investigated Olympic trial basketball players and found a higher incidence of knee injuries among women (34 of 64) than among men (11 of 80). The severity and requirement for surgery were also statistically higher. These studies indicate the
Quinidine Dementia
Authors: Gordon J. Gilbert
Journal: JAMA (1977)

USED primarily in the treatment of atrial fibrillation and certain other cardiac arrhythmias, quinidine is well recognized to be a dangerous as well as an effective drug. Occasionally the introduction of even small doses may cause tinnitus, vertigo, visual disturbance, headache, and confusion.<sup>1</sup> A new and treatable cause of progressive dementia was found in a woman receiving quinidine for 14 years after an acute myocardial infarction; moreover, the discontinuation of quinidine led to a remarkable and progressive recovery of intellectual faculties. <h3>Report of a Case</h3> A 72-year-old woman was hospitalized on Jan 30, 1976, because of a severe memory loss and chronic confusional state of several years' duration. Because of disorientation for time and place and greatly impaired memory, she had come to rely on written lists of whatever she wanted to do. She could not perform household tasks any longer, cope with small sums of money, remember a
EVALUATION OF BLOOD BRAIN BARRIER PERMEABILITY IN HUMAN BRAIN TUMORS WITH POSITRON TOMOGRAPHY AND Ga-68 EDTA.
Authors: Randall A. Hawkins, Peter D. Grimm, Joseph A. Wapenski, Sung-Cheng Huang, Peter Greenberg, Michael E. Phelps, Robert G. Parker, Guy Juillard, David E. Kuhl
Journal: Clinical Nuclear Medicine (1983)

Hawkins, Randall A.; Grimm, Peter D.; Wapenski, Joseph A.; Huang, Sung-Cheng; Greenberg, Peter; Phelps, Michael E.; Parker, Robert G.; Juillard, Guy; Kuhl, David E. Author Information
Infiltrating
Authors: Amishi Bajaj
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 231: A Hand1 Left Ventricular Enhancer that is Associated With Prolonged QRS Interval
Authors: Joshua W Vincentz, Wenjun Zhang, Weinian Shou, Dan Arking, Nona Sotoodehnia, Michael Rubart-von der Lohe, Anthony B Firulli
Journal: Circulation Research (2017)

Throughout the process of cardiogenesis, dynamic changes in cardiomyocyte morphology are defined by gene regulatory networks that drive atrial, ventricular, septal, compact zone or trabecular cardiomyocyte cellular identity. The bHLH transcription factors Hand1 and Hand2 are both critical for heart development. We have isolated a 750 bp evolutionarily conserved non-coding sequence 5’ to the Hand1 transcription start site that is necessary and sufficient to drive left ventricle (LV)-specific Hand1 expression. Regulatory cis -elements include Gata and T-box binding sights. We show this enhancer as necessary and sufficient for LV expression using CrispR/Cas9 deletion. Mice homozygous for this enhancer deletion ( Hand1 αLV/ αLV ) are viable and fertile. Adult Hand1 αLV/ αLV mice exhibit a prolonged QRS interval. Interestingly, human HAND1 SNPs associated with prolonged QRS are located near the LV enhancer, but these SNP sequences are not conserved in mice. More refined examination of the human sequences revealed additional prolonged QRS-associated human nucleotide changes occurring directly within the conserved enhancer that alter cis -element DNA binding. Ventricular conduction system gene expression is altered in Hand1 enhancer deletion mice, validating in vivo a human GWAS association study that links Hand1 function to the development and perhaps maintenance of the LV purkinje fiber network. Additionally, using the Hand1 LV-enhancer, we have generated a novel Cre transgenic mouse line ( Hand1 LV -Cre ), in which LV-specific recombination is observed. We use this Cre to delete both cardiomyocytes and Hand genes from the developing LV, discovering that specification of subpopulations of ventricular cardiomyocytes regulates myocardial growth and, thereby, cardiac function.
Editorial Board
Authors: Bruce Thiers, Dirk Elston, Detra Davis, Anna Krueger, Kenneth Katz, Jack Lesher, Mary Spellman, Jeffrey Weinberg, Dermatologic Surgery, Clifford Perlis, Julie Prendiville, Frcpc Dermatopathology, John Maize, Social Media, Emily Altman, Robert Dellavalle, J Smith, Dermatoethics Consultations, Lionel Bercovitch, Jane Grant-Kels, Robert Brodell, Kelly Cordoro, Edward Cowen, Carlos Garcia, Christopher Miller, Desiree Ratner, Brett Sloan, Hensin Tsao, Matthew Zirwas, Giuseppe Argenziano, Haines Ely, Tammie Ferringer, Kavita Mariwalla, Giuseppe Micali, Angela Moore, Alexander Stratigos, Christophe Hsu
Journal: Journal of the American Academy of Dermatology (2015)
Regulation of insulin-like growth factor II gene expression by hepatitis B virus in hepatocellular carcinoma
Authors: C d'Arville
Journal: Hepatology (1991)

In this study we investigated the regulation of insulin-like growth factor II gene expression to explain a role for this growth factor in concert with hepatitis B virus involvement in the development of hepatocellular carcinoma from cirrhosis. Sections of normal liver and tumor and non-tumorbearing liver disease tissue were hybridized in situ with [35S]-labeled insulin-like growth factor II oligonucleotide probe. Parallel sections were tested for presence of insulin-like growth factor II polypeptide using immunohistochemistry. To investigate a possible role for hepatitis B virus in insulin-like growth factor II gene expression in hepatocellular carcinoma, results were analyzed against patient seropositivity for hepatitis B virus. Levels of insulin-like growth factor II transcripts in normal liver (n = 4) sections and in those from nontumor-bearing individuals (n = 10) were so low that specific signal was not detectable above homogeneous tissue background. In contrast, 4 of 8 (50%) of the sections of hepatocellular carcinoma arising from cirrhosis or noncirrhotic chronic liver disease with hepatitis B virus involvement showed increased expression of insulin-like growth factor II messenger RNA transcripts. Up-regulation was observed in cell foci in the hepatocellular regions of the surrounding cirrhotic lobular cells and the fibrous septa. Numerous cell foci were observed in patchy distribution in the tumor areas. The level of insulin-like growth factor II messenger RNA transcripts in sections of hepatocellular carcinoma arising from cirrhotic and noncirrhotic tissues obtained from patients seronegative for hepatitis B virus was similar to that of normal liver. Immunohistochemical study demonstrated that similar cells in the cirrhotic liver lobules containing insulin-like growth factor II messenger RNA transcripts also contained immunoreactive polypeptide. In contrast, we saw no positive staining for insulin-like growth factor II in tumor cells. These results imply a role for insulin-like growth factor II in the pathogenesis of cirrhotic/noncirrhotic chronic liver disease to hepatocellular carcinoma where there is evidence of hepatitis B virus involvement. Alterations in posttranscriptional events for insulin-like growth factor II in tumor cells may contribute to the maintenance or progression of the malignant phenotype. (HEPATOLOGY 1991;13:310–315).
OC-050 5-Aminosalicylate (5-Asa) Induced Nephrotoxicity in Inflammatory Bowel Disease
Authors: K So, C Bewshea, G A Heap, A F Muller, T K Daneshmend, A L Hart, T R Orchard, P M Irving, R K Russell, D C Wilson, M Parkes, J Satsangi, C W Lees, T Ahmad
Journal: Gut (2013)

<h3>Introduction</h3> Nephrotoxicity is a rare idiosyncratic reaction to 5-ASA therapy. The precise pathogenic mechanisms are unknown. This study aims to a) describe the clinical features of this rare complication b) explore underlying mechanisms and c) identify clinically useful predictive genetic markers so these drugs can be avoided, or monitoring intensified, in high-risk patients. Here we report the clinical features. <h3>Methods</h3> Patients were identified and recruited from 185 sites (130 UK). Inclusion criteria included normal renal function prior to commencing 5-ASA, ≥50% rise in creatinine after starting 5-ASA and medical opinion implicating 5-ASA justified drug withdrawal. An adjudication panel assessed causality from case report forms using the validated Liverpool Adverse Drug Reaction Causality Assessment Tool. <h3>Results</h3> 154 patients were recruited. 19 patients were excluded following adjudication. The cohort included patients with Crohn's disease, ulcerative colitis and indeterminate colitis (42%, 55%, 4% respectively). 74% of cases were male. Nephrotoxicity was seen with all aminosalicylates including 1 patient treated with topical therapy only. Nephrotoxicity occurred at a median age of 36.5 yrs (range 15.4–88.4 yrs). Two patients had a confirmed family history of 5-ASA-induced nephrotoxicity. 78% were detected by routine blood monitoring. Only 45% of cases recovered completely after drug withdrawal, with 18 requiring renal replacement therapy (14 transplantation). The median time for peak creatinine after commencing 5-ASA was 3.5 yrs (range 0.16–43.4 yrs). There was no evidence that time on 5-ASA treatment was associated with a higher peak creatinine or the likelihood of full recovery (p = 0.87). Women were more likely to reach full recovery than men (p = 0.00148; OR 8.26; CI 2.46–34.94). There was no evidence that early withdrawal of 5-ASA led to a higher likelihood of complete recovery. There was no difference in recovery between the three disease groups on logistic regression analysis. <h3>Conclusion</h3> This is the largest and most detailed study of 5-ASA induced nephrotoxicity to date. Whilst the incidence is low, the morbidity is high with 13% of patients requiring renal replacement therapy and 55% of patients failing to return to a normal creatinine after 5-ASA withdrawal. The next step is to carry forward these patients to a genome-wide association analysis, to be performed in February 2013. <h3>Disclosure of Interest</h3> None Declared
Handbook of the Diagnosis and Treatment of Skin Diseases.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bridging the global health gap
Authors: None The Lancet Global Health
Journal: The Lancet Global Health (2016)

If there is one constant in the evolving global health agenda, it is the need to address disparities in health. The often-made distinction between inequality and inequity is important: the former simply describes a difference between two measurements of the same indicator, while the latter includes the notion that this difference is unjust or wrong. Whatever the term used, the endpoint is the same: there are notable variations in health outcomes between population groups, and one of the goals of global health practitioners is to reduce them.
A SACRAL TERATOMA CONTAINING AN EMBRYONIC SCAPULA
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reye syndrome with associated influenza A and B infection
Authors: F. L. Ruben
Journal: JAMA (1975)

In early 1974, seventeen children were treated for Reye syndrome. Thirteen of these were studied for laboratory evidence of concomitant viral infection. Influenza B/Hong Kong was isolated from the pharynx in four of nine 1974 cases tested. One child had just recovered from varicella. Adenovirus type 2 and respiratory syncytial virus were isolated from two additional patients. Serologic tests for influenza suggested concomitant or recent influenza B infection in ten of 13 of 1974 cases. During February 1975, six children were treated for this syndrome. Influenza A/Port Chalmers was recovered from three in six 1975 cases, and all six showed significant antibody rises to influenza A. These studies suggest that influenza viruses provide a trigger mechanism for the development of Reye syndrome in susceptible children. (<i>JAMA</i>234:410-412, 1975)